The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)
Abstract
Objective: To investigate the efficacy and tolerability of infliximab therapy for the articular and dermatologic manifestations of active psoriatic arthritis (PsA). Methods: One hundred four patients with PsA in whom prior therapy with at least 1 disease‐modifying antirheumatic drug (DMARD) had failed were recruited into this investigator‐initiated, multicenter, randomized, double‐blind, placebo‐controlled clinical trial. During the initial blinded portion of the study, patients received infusions of infliximab (5 mg/kg) or placebo at weeks 0, 2, 6, and 14. After week 16, patients initially assigned to receive placebo crossed over to receive infliximab 5 mg/kg every 8 weeks through week 50, while patients initially randomized to infliximab continued to receive active treatment at the same dose through week 50. The primary efficacy outcome was achievement of the American College of Rheumatology 20% criteria for improvement in rheumatoid arthritis (ACR20) at week 16. Additional predefined clinical efficacy assessments included the Psoriasis Area and Severity Index (PASI) score, the ACR50 and ACR70 criteria, the Disease Activity Score in 28 joints, the Health Assessment Questionnaire, ratings of enthesitis and dactylitis, and the Psoriatic Arthritis Response Criteria score. Results: The proportion of infliximab‐treated patients who achieved an ACR20 response at week 16 (65%) was significantly higher than the proportion of placebo‐treated patients who achieved this response (10%). In addition, 46% of infliximab‐treated patients achieved an ACR50 response, and 29% achieved an ACR70 response; no placebo‐treated patient achieved these end points. Among patients who had PASI scores of ≥2.5 at baseline, 68% of infliximab‐treated patients achieved improvement of ≥75% in the PASI score at week 16 compared with none of the placebo‐treated patients. Continued therapy with infliximab resulted in sustained improvement in articular and dermatologic manifestations of PsA through week 50. The incidence of adverse events was similar between the treatment groups. Conclusion: Therapy with infliximab at a dose of 5 mg/kg significantly improved the signs and symptoms of arthritis, psoriasis, dactylitis, and enthesitis in patients with active PsA that had been resistant to DMARD therapy. With continued infliximab treatment, benefits were sustained through 50 weeks. The benefit‐to‐risk ratio appeared favorable in this study population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevoo, M. L. L., Van'T Hof, M. A., Kuper, H. H., Van Leeuwen, M. A., Van De Putte, L. B. A., & Van Riel, P. L. C. M. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380107 · Cited by 6,243
Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis
Lipsky, P. E., van der Heijde, D. M. F. M., St. Clair, E. W., Furst, D. E., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Weisman, M., Emery, P., Feldmann, M., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011303432202 · Cited by 2,996
Self-citationAmerican college of rheumatology preliminary definition of improvement in rheumatoid arthritis
Felson, D. T., Anderson, J. J., Boers, M., Bombardier, C., Furst, D., Goldsmith, C., Katz, L. M., Lightfoot, R., Paulus, H., Strand, V., et al. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380602 · Cited by 2,829
Self-citationSevere Psoriasis – Oral Therapy with a New Retinoid
Fredriksson, T., & Pettersson, U. (2009) · Dermatologica · doi:10.1159/000250839 · Cited by 2,718
Maini, R., St Clair, E. W., Breedveld, F., Furst, D., Kalden, J., Weisman, M., Smolen, J., Emery, P., Harriman, G., Feldmann, M., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)05246-0 · Cited by 2,345
Self-citationMaini, R. N., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Davis, D., MACFARLANE, J. D., Antoni, C., Leeb, B. F., Elliott, M. J., Woody, J. N., et al. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199809)41:9<1552::aid-art5>3.0.co;2-w · Cited by 1,623
Self-citationEtanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial
Mease, P. J., Goffe, B. S., Metz, J., VanderStoep, A., Finck, B., & Burge, D. J. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02530-7 · Cited by 1,446
Etanercept as Monotherapy in Patients with Psoriasis
Leonardi, C. L., Powers, J. L., Matheson, R. T., Goffe, B. S., Zitnik, R., Wang, A., & Gottlieb, A. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030409 · Cited by 1,175
INFLIXIMAB AND METHOTREXATE IN THE TREATMENT OF RHEUMATOID ARTHRITIS
Ipsky, P. E. E. L., Illiam, E. W., Urst, D. A. E. F., Reedveld, C. B., Oachim, J., Alden, R. K., Osef, J., Molen, S. S., Eisman, M. I. W., Mery, P. A. E., et al. (2000) · Cited by 1,155
van der Heijde, D. M., van 't Hof, M. A., van Riel, P. L., Theunisse, L. A., Lubberts, E. W., van Leeuwen, M. A., van Rijswijk, M. H., & van de Putte, L. B. (1990) · Annals of the Rheumatic Diseases · doi:10.1136/ard.49.11.916 · Cited by 1,087
Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial
Chaudhari, U., Romano, P., Mulcahy, L., Dooley, L., Baker, D., & Gottlieb, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04954-0 · Cited by 890
Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression
Mease, P. J., Kivitz, A. J., Burch, F. X., Siegel, E. L., Cohen, S. B., Ory, P., Salonen, D., Rubenstein, J., Sharp, J. T., & Tsuji, W. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20335 · Cited by 882
Elevated tumour necrosis factor-alpha (TNF-α) biological activity in psoriatic skin lesions
ETTEHADI, P., GREAVES, M. W., WALLACH, D., ADERKA, D., & CAMP, R. D. R. (2008) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.1994.tb06244.x · Cited by 481
Clegg, D. O., Reda, D. J., Mejias, E., Cannon, G. W., Weisman, M. H., Taylor, T., Budiman‐Mak, E., Blackburn, W. D., Vasey, F. B., Mahowald, M. L., et al. (1996) · Arthritis & Rheumatism · doi:10.1002/art.1780391210 · Cited by 447
Self-citationKaltwasser, J. P., Nash, P., Gladman, D., Rosen, C. F., Behrens, F., Jones, P., Wollenhaupt, J., Falk, F. G., & Mease, P. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20253 · Cited by 413
Self-citationPincus, T., Swearingen, C., & Wolfe, F. (1999) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199910)42:10<2220::aid-anr26>3.0.co;2-5 · Cited by 407
Wong, K., Gladman, D. D., Husted, J., Long, J. A., Farewell, V. T., & Long, J. A. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780401021 · Cited by 339
Self-citationGladman, D. D., Farewell, V. T., Wong, K., & Husted, J. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199806)41:6<1103::aid-art18>3.0.co;2-n · Cited by 314
Self-citationPartsch, G., Steiner, G. E., Leeb, B. F., Dunky, A., Bröll, H., & Smolen, J. S. (1997) · PubMed · Cited by 297
Self-citationPatterns of cytokine production in psoriatic synovium.
Ritchlin, C. T., Haas-Smith, S. A., Hicks, D. G., Cappuccio, J. A., Osterland, C. K., & Looney, R. J. (1998) · PubMed · Cited by 291
Willkens, R. F., Williams, H. J., Ward, J. R., Egger, M. J., Reading, J. C., Clements, P. J., Cathcart, E. S., Samuelson, C. O., Solsky, M. A., Kaplan, S. B., et al. (1984) · Arthritis & Rheumatism · doi:10.1002/art.1780270403 · Cited by 289
The pathogenesis of psoriasis: immunological facts and speculations
Bos, J. D., & De Rie, M. A. (1999) · Immunology Today · doi:10.1016/s0167-5699(98)01381-4 · Cited by 284
CLASSIFICATION OF CLINICAL SUBSETS EN PSORIATIC ARTHRITIS
VEALE, D., ROGERS, S., & FITZGERALD, O. (1994) · Rheumatology · doi:10.1093/rheumatology/33.2.133 · Cited by 208
Antoni, C., Dechant, C., Hanns‐Martin Lorenz, P. D., Wendler, J., Ogilvie, A., Lueftl, M., Kalden‐Nemeth, D., Kalden, J. R., & Manger, B. (2002) · Arthritis Care & Research · doi:10.1002/art.10671 · Cited by 177
Self-citationComparison of radiological severity in psoriatic arthritis and rheumatoid arthritis.
Rahman, P., Nguyen, E., Cheung, C., Schentag, C. T., & Gladman, D. D. (2001) · PubMed · Cited by 94
Self-citation
Cited by
TNF-mediated inflammatory disease
Bradley, Jr. (2008) · The Journal of Pathology · doi:10.1002/path.2287 · Cited by 2,094
Guidelines of care for the management of psoriasis and psoriatic arthritis
Menter, A., Gottlieb, A., Feldman, S. R., Van Voorhees, A. S., Leonardi, C. L., Gordon, K. B., Lebwohl, M., Koo, J. Y. M., Elmets, C. A., Korman, N. J., et al. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2008.02.039 · Cited by 1,222
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics
Menter, A., Strober, B. E., Kaplan, D. H., Kivelevitch, D., Prater, E. F., Stoff, B., Armstrong, A. W., Connor, C., Cordoro, K. M., Davis, D. M. R., et al. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.11.057 · Cited by 969
Self-citationMease, P. J., Gladman, D. D., Ritchlin, C. T., Ruderman, E. M., Steinfeld, S. D., Choy, E. H. S., Sharp, J. T., Ory, P. A., Perdok, R. J., & Weinberg, M. A. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21306 · Cited by 909
Self-citationvan der Heijde, D., Kivitz, A., Schiff, M. H., Sieper, J., Dijkmans, B. A. C., Braun, J., Dougados, M., Reveille, J. D., Wong, R. L., Kupper, H., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21913 · Cited by 872
Metadata
- Authors
- Antoni, C. E., Kavanaugh, A., Kirkham, B., Tutuncu, Z., Burmester, G. R., Schneider, U., Furst, D. E., Molitor, J., Keystone, E., Gladman, D., Manger, B., Wassenberg, S., Weier, R., Wallace, D. J., Weisman, M. H., Kalden, J. R., & Smolen, J.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2005-04
- Volume
- 52
- Issue
- 4
- Pages
- 1227-1236
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2094124191
- Cited by
- 640
- References
- 25
- FWCI
- 35.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.